ALK-B.CO - ALK-Abelló A/S
| Previous close | 82.00 |
| Open | 82.35 |
| Bid | 83.15 x 0 |
| Ask | 83.30 x 0 |
| Day's range | 82.05 - 83.45 |
| 52-week range | 80.75 - 156.20 |
| Volume | |
| Avg. volume | 570,138 |
| Market cap | 18.376B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 55.43 |
| EPS (TTM) | 1.50 |
| Earnings date | 24 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Mar 2017 |
| 1y target est | 136.83 |
Globe NewswireThree-month interim report (Q1) 2023
Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic revenue growth in local currencies and increased operating profit with an EBIT margin of 18%. Combined SCIT and SLIT-drops sales exceeded expectations, while tablet sales were around DKK 35 million lower than planned on slower growth in new patient initiations. The full-year revenue and earnings outlook remains unchanged. Q1 2023 financial highlights Comparative figu
- Globe Newswire
Release date of three-month interim report (Q1) 2023 for ALK and audio cast
On Tuesday, 9 May 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its three-month interim report (Q1) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CEST) at which Management will review the financial results, the outlook and answer questions. The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins. Participants in the conference call are kindly requested
- Globe Newswire
ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook
ALK’s (ALKB:DC / OMX: ALK B / AKBLF) overall results in Q1 2023 were largely as expected with 7% organic revenue growth in local currencies and increasing operating profit (EBIT). Combined SCIT and SLIT-drops sales exceeded expectations. Tablet sales were lower than planned due to the temporary effect from a major wave of respiratory infections constraining new patient initiations in parts of Europe, most notably in Germany and the Nordics. Preliminary financial highlights from Q1 2023 Comparati
- Globe Newswire
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
ALK (ALKB:DC / OMX: ALK B / AKBLF): According to the Company’s remuneration policy adopted at the Company's Annual General Meeting on 23 March 2023 and in line with the Company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 651,000 share-based instruments for the purpose of the Company’s long-term incentive plan (LTIP) for the Board of Management and key employees for 2023. The objectives of the LTIP are to incentivise and reward long-term value creati
- Globe Newswire
Annual General Meeting in ALK-Abelló A/S held on 23 March 2023
ALK (ALKB:DC / OMX: ALK B / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 23 March 2023. The Annual General Meeting transacted the following business: Adoption of the annual report 2022 and discharge of the Board of Directors and Board of ManagementNo declaration of ordinary dividend in accordance with the approved annual report for 2022Adoption of the remuneration report for 2022Adoption of the remuneration to the Board of Directors for the present yearRe-election of Anders Hedegaar
- Globe Newswire
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff: The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 5/2020 of 19 March 2020. The right to share options and performance shares may be achieved in March 2023, provided that ALK achie
- Globe Newswire
Annual General Meeting in ALK on 23 March 2023
ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 23 March 2023 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK
- Globe Newswire
ALK appoints Claus Steensen Sølje as new Chief Financial Officer (CFO)
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that Claus Steensen Sølje will take up the position as Executive Vice President, Chief Financial Officer (CFO) and member of the Board of Management no later than 1 June 2023. He succeeds Søren Jelert, whose decision to leave ALK was announced in November 2022. Claus Steensen Sølje, born 1972, a Danish citizen, will bring extensive experience to ALK from more than 20 years in various leadership roles at Novo Nordisk in Denmark, France and Switze
- Globe Newswire
Regulatory filing for house dust mite allergy tablet accepted for review in China
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that its Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (AIT) tablet has been accepted for review by the National Medical Products Administration (NMPA) in China. The BLA, for treatment of persistent moderate-to-severe HDM allergic rhinitis in patients aged 12–65 was submitted in late December 2022. Søren Niegel, ALK's Executive Vice President, Commercial Operations, says: “This is an important
- Globe Newswire
Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022
ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2022 annual report (ESEF-version ALK-2022-12-31-en attached). Following a solid Q4, full-year results exceeded initial expectations and were in line with the most recent outlook. ALK expects to continue its trajectory of growth and earnings improvement in 2023. (Revenue growth rates are stated in local currencies. Comparative figures for 2021 are shown in brackets) Q4 2022 highlights Revenue grew by 12% to an all-
- Globe Newswire
Release date of annual report 2022 for ALK and audio cast
On Friday, 3 February 2023 expectedly around noon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report for 2022. ALK will host a meeting for analysts and institutional investors that day at 2.00pm (CET) at which Management will review the financial results, the outlook and answer questions. The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins. Participants in the conference call are kin
- Globe Newswire
Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Henriette Mersebach will take up the position as Executive Vice President, Research & Development and member of the Board of Management expectedly on 1 March 2023. She replaces Henrik Jacobi, who wishes to retire from the position after 22 years with ALK, hereof 19 years as Executive Vice President, Research & Development. To facilitate a smooth generational change, Henrik Jacobi will continue in his present role until Henriette Mer
- Globe Newswire
ALK – Financial calendar for the 2023 financial year
2023 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): 6 January 2023: Silent period3 February 2023: Annual report 202223 March 2023 at 4.00p.m.: Annual General Meeting to be held at ALKBøge Allé 12970 Hørsholm, Denmark Written requests to have specific business transacted at the AGM will be included in the agenda if received by the company on 8 February 2023 at the latest (may be e-mailed to investor@alk.net) 11 April 2023: Silent period9 May 2023: Three-month interim report (Q
- Globe Newswire
Management change at ALK
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Søren Jelert, Executive Vice President, CFO and member of the Board of Management, has decided to resign his position to join a company in another sector and will expectedly leave ALK on 31 May 2023. Chairman of the Board of Directors, Anders Hedegaard, and President & CEO, Carsten Hellmann said: "We would like to offer our sincere thanks to Søren for his pivotal role in ALK's transformation over the past five years. We wish him the
- Globe Newswire
Nine-month interim report (Q3) 2022
ALK reports Q3 revenue up 11% and updates its full-year outlook (unaudited) ALK’s revenue grew by 11% in Q3 driven by tablets and Jext®, with growth in all regions. Year-to-date revenue grew 13%, with tablet sales up 19% and profits up 27%. Based on stronger sales in the non-tablet portfolio, ALK is updating its full-year outlook. Q3 2022 financial highlights Total revenue was up 11% in local currencies at DKK 1,062 million (928). Currencies had a positive effect of 3 percentage points, resultin
- Globe Newswire
Release date of nine-month interim report (Q3) 2022 for ALK and audio cast
On Thursday, 10 November 2022, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its nine-month interim report (Q3) 2022. ALK will host a meeting for analysts and institutional investors that day at 1.30 pm (CET) at which Management will review the financial results, the outlook and answer questions. The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins. Participants in the conference call are k
- Globe Newswire
Six-month interim report (Q2) 2022
ALK reports Q2 revenue up 17%, EBITDA up 123%, and full-year outlook upgraded (unaudited) Performance in Q2 was better than expected with double-digit growth in all regions and ALK reported its best-ever Q2 results. Total revenue was up 17% led by sales growth from tablets and Jext®. In Europe, ALK’s largest region, sales were up 14% and bounced back strongly after the COVID-led headwinds of Q1. Operating profit (EBITDA) increased 123% on sales growth and improved gross margin. Based on the stro
- Globe Newswire
Release date of six-month interim report (Q2) 2022 for ALK and audio cast
On Thursday, 11 August 2022, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its six-month interim report (Q2) 2022. ALK will host a meeting for analysts and institutional investors that day at 1.30 pm (CEST) at which Management will review the financial results, the outlook and answer questions. The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins. Participants in the conference call are kin
- Globe Newswire
ALK upgrades its full-year financial outlook
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that based on a strong sales momentum and the outlook for the remainder of the year, ALK has upgraded its full-year outlook. As a result: Revenue is now expected to grow 10-13% in local currencies (previously: 8-12%).EBITDA is now expected to increase to DKK 675-750 million (previously: 625-725). ALK will publish its Q2 performance in connection with the six-month interim report on 11 August 2022. ALK-Abelló A/S For further information p
- Globe Newswire
ALK spotlights the impact of respiratory allergies on children at EAACI Congress
Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the EAACI CongressThe growing availability of evidence-based allergy immunotherapy treatments for paediatric patients offers increased treatment options for prescribersALK has enrolled more than 3,000 paediatric patients in eight Phase III clinical trials of its SLIT-tablets, as it pursues indications for children and adolescents around the world ALK has thrown a
- Globe Newswire
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy. The trial marks the formal start of clinical development of the peanut SLIT-tablet which uses same technology as ALK’s SLIT-tablets for respiratory allergies. ALK announced today that it is initiating Phase I clinical development of its investigational SLIT-tablet for the treatment of peanut allergy. Un